| Cancer name | Non Small Cell Lung Cancer |
| Cancer Type | NSCLC |
| Immunotherapy type | Immune Checkpoint Therapy |
| Treatment | nivolumab |
| Drugstatus | Approved |
| Drugbank ID | DB09035 |
| Checkpoints | PD-1 |
| Signature Type | Protein |
| Signature | IFNG |
| Official Symbol | IFNG |
| Mode of action | TRAN_R_UP |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | clinical trail |
| Description | With a median follow up of 15.7 (95% CI 3.4–23.0) months, median progression-free survival was 2 months (95% CI 0.5–3.1) and 5.1 (95% CI 1.4–15.2) months for patients with low and high IFNG mRNA, respectively (p=0.0124), [HR for disease progression, 6.66; 95% I 1.20–36.79; p= 0.0297; Figure 2(a); Table 4]. Univariate analysis revealed that low IFNG mRNA expression was significantly associated with shorter progression-free survival. IFNG mRNA expression was not significantly associated with the survival of the patients but a clinically relevant difference was found. Specifically, median overall survival was 4.9 months (95% CI 0.5–8.7) and 10.2 [95% CI 0.8–NR (not reached)] months for patients with low and high IFNG mRNA, respectively (p= 0.0687), (HR for death, 4.10; 95% CI 0.80–20.83; p= 0.0911) . |
| PMID | 29383037 |
| Title | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients |